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Background: Cystic fibrosis (CF) is a monogenic disease caused by CFTR gene mutations, with clinical expression
similar to complex disease, influenced by genetic and environmental factors. Among the possible modifier genes, those
associated to metabolic pathways of glutathione (GSH) have been considered as potential modulators of CF clinical
severity. In this way it is of pivotal importance investigate gene polymorphisms at Glutamate-Cysteine Ligase, Catalytic
Subunit (GCLC), Glutathione S-transferase Mu 1 (GSTM1), Glutathione S-transferase Theta 1 (GSTT1), and Glutathione
S-transferase P1 (GSTP1), which have been associated to the GSH metabolic pathway and CF clinical severity.
Method: A total of 180 CF’s patients were included in this study, which investigated polymorphisms in GCLC and GST
genes (GCLC -129C>T and -3506A>G; GSTM1 and GSTT1 genes deletion, and GSTP1*+313A>G) by PCR and PCR-RFLP
associating to clinical variables of CF severity, including variables of sex, clinical scores [Shwachman-Kulczycki, Kanga e Bhalla
(BS)], body mass index, patient age, age for diagnosis, first clinical symptoms, first colonization by Pseudomonas aeruginosa,
sputum’s microorganisms, hemoglobin oxygen saturation in the blood, spirometry and comorbidities. The CFTR genotype
was investigated in all patients, and the genetic interaction was performed using MDR2.0 and MDRPT0.4.7 software.
Results: The analysis of multiple genes in metabolic pathways in diseases with variable clinical expression, as CF
disease, enables understanding of phenotypic diversity. Our data show evidence of interaction between the GSTM1 and
GSTT1 genes deletion, and GSTP1*+313A>G polymorphism with CFTR gene mutation classes, and BS (Balance testing
accuracy= 0.6824, p= 0.008), which measures the commitment of bronchopulmonary segments by tomography.
Conclusion: Polymorphisms in genes associated with metabolism of GSH act on the CF’s severity.Background
Cystic Fibrosis (CF) is a common disease in Caucasian
population, with a prevalence of 1:2,500 live births [1]. CF
shows an autosomal recessive pattern of inheritance [2],
which is caused by mutations in Cystic Fibrosis Transmem-
brane Regulator (CFTR) gene. More than 1,900 mutations
in CFTR gene have been associated to CF clinical severity
[3-6]. However, in the pulmonary disease, which is the
main cause of CF morbidity and mortality, several studies
have demonstrated that clinical variability is influenced by
modifier genes and environmental factors [2,7].
Most of modifier genes related to CF have been
associated with chloride transportation, infection and
inflammation in the lungs [2,7-10]. In our group, as* Correspondence: fernandolimamarson@hotmail.com
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reproduction in any medium, provided the orpreviously published, multiple genes are associated with
CF clinical severity, including Transforming growth factor
beta 1 (TGF-β1) [11], Glutathione S-transferase Mu 1
(GSTM1), Glutathione S-transferase Theta 1 (GSTT1)
[12], Angiotensin-converting enzyme (ACE) [13] and Beta-
2-Adrenergic Receptor (ADBR2) [14] genes as possibly
modifier genes. In the same population the mannose-
binding lectin (protein C) 2 (MBL2) and monocyte differ-
entiation antigen CD14 (CD14) genes were not associated
with the CF clinical severity [11].
Glutathione (GSH) is a tripeptide involved in the intra-
cellular defense system, which protect the epithelium
against injuries and inflammation, both common events
of CF [15]. Polymorphisms in regulator genes of GSH
metabolic pathway have been described in CF, including
Glutathione S-transferase P1 (GSTP1), GSTT1, GSTM1
and Glutamate-Cysteine Ligase, Catalytic Subunit (GCLC)
genes, which have been associated with greater CF clinicalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical features of cystic fibrosis patients included
in the study
Sex (male) 50% (80)#
Age 17.72 ± 15.75 years (0.6 – 24 years)*
BMI - thinness and accentuated thinness 22.22% (40)#
One Class I. II or III identified mutation 28.33% (51)#
Two Class I. II or III identified mutation 47.22% (85)#
First clinical manifestation 2.90 ± 8.89 years (0 – 13 years)*
Age at diagnosis 7.62 ± 13.63 years (0 – 14.23 years)*
Onset of digestive symptoms 3.39 ± 9.11 years (0 – 12.45 years)*
Onset of pulmonary symptoms 2.90 ± 9.89 years (0 – 13 years)*
SpO2 94.92 ± 4.26 (66 – 99)*
Bhalla score 8.74 ± 5.724 (0 – 25)*
Kanga score 18.85 ± 5.84 (10 – 40)*
Shwachman-Kulczycki score 65.85 ± 16.77 (20 – 95)*
FVC (%) 79.29 ± 23.55 (19 – 135)*
FEV1 (%) 71.29 ± 27.47 (17 – 132)*
FEV1/FVC (%) 83.46 ± 15.95 (37 – 137)*
FEF25-75% 59.05 ± 35.55 (7 – 150)*
Nasal Polyps 18.33% (33)#
Diabetes mellitus 18.33% (33)#
Osteoporosis 16.11% (29)#
Pancreatic insufficiency 80.0% (144)#
Meconium ileus 15.00% (27)#
First isolated P. aeruginosa 8.55 ± 14.45 years (2 – 15 years)
P. aeruginosa status 56.67% (102)#
P. aeruginosa mucoid status 42.22% (76)#
B. cepacia status 13.88% (25)#
A. xylosoxidans status 10.00% (18)#
S. aureus status 78.88% (142)#
BMI body mass index, SpO2 Hemoglobin oxygen saturation in the blood, %
percentage, FVC forced vital capacity, FEV1 forced expiratory volume in the
first second, FEF25-75 forced expiratory flow between 25 and 75% of FVC. 2.
Based on 3 Consecutive positive respiratory cultures.
# Percentage (Number of patients).
* Continuous variables expressed as mean ± SD (range).
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and -3506A>G] polymorphisms gene has not been yet
evaluated for pulmonary disease variability in CF.
GCLC gene encodes the catalytic subunit of glutamate-
cysteine ligase (GCL) [24], which is the first limiting en-
zyme in the GSH synthesis [25]. Polymorphisms -129C>T
and -3506A>G, located in GCLC gene promoter region,
have been associated to reduced GSH production [15,25].
The Glutathione S-transferase (GST) is a family of en-
zymes, which associates GSH and causative compounds
of oxidative stress, to a wide variety of endogenous (e.g.
by-products of reactive oxygen species activity) and ex-
ogenous (e.g. polycyclic aromatic hydrocarbons) electro-
philic substrates [26]. Polymorphisms in GST family
genes can also be involved in CF’s severity [15,26], espe-
cially in pulmonary disease, including GSTM1, GSTT1
and GSTP1 genes [15,19,20,26-28].
In our referral center, we have observed clinical variabil-
ity among CF’s patients. However, the patients present
similar socioeconomic status, none severe malnutrition,
mutations of classes I, II and/or III, similar support of the
Parents Association (www.fibrocis.org.br), and receive free
medication by the government. Therefore, we postulate
that clinical variability could be associated with interaction
of polymorphisms in modifier genes. In this context, we
aim to analyze polymorphisms in GCLC and GST genes
(GCLC -129C>T and -3506A>G; GSTM1 and GSTT1
genes deletion, and GSTP1*+313A>G) associating to clin-
ical markers of CF severity.
Methods
Ascertainment of patients
It was conducted a cross-sectional study and patients were
selected during the period of 2010 and 2011, in a university
center for CF patients care. This study was approved by
Ethics Research Board of the Faculty of Medical Sciences
at University of Campinas - São Paulo – Brazil (#528/
2008). The study was in accordance to the Helsinki declar-
ation and all patients signed a consent form before begin-
ning the study. For patients below the age of 18 the
consent was granted by their parents or guardians.
Diagnosis of CF was confirmed in patients with two
doses of sodium and chloride from the sweat with values
greater than 60 mEq/L. In a group of patients we identi-
fied two CFTR gene mutations. No patient had received
neonatal screening test performed for CF. A total of 215
patients were selected for the study. Among them, 35 pa-
tients without clinical data for statistical analysis and those
who did not sign the consent form were excluded from
the study, and 180 CF patients were included at the study.
Clinical variables
The following clinical variables were employed: clinical
scores [Shwachman-Kulczycki (two groups: ≤ 65 and > 65),Kanga (two groups: ≤ 17 and > 17) and Bhalla (BS) (two
groups: ≤ 8 and > 8)] [29]; body mass index (BMI) [for
the patients older than 19 years the BMI= weight/(height)2
formula was used; for the remaining patients the WHO
ANTHRO programs (children under 5 years old) and
WHO ANTHRO PLUS (children 5 - under 19 years old)
[30,31] were used; patient age (group: ≤ 154 and > 154
months) and age at diagnosis (according to the sodium
and chloride in altered perspiration: ≤ 25 and > 25
months); first clinical symptoms [(digestive: ≤ 4 and > 4
months; pulmonary: ≤ 7 and > 7months)]; the period
up to first colonization by Pseudomonas aeruginosa
(≤ 31 and > 31 months); sputum’s microorganisms
[P. aeruginosa mucoid and non mucoid, Achromobacter
xylosoxidans, Burkolderia cepacia and Staphylococcus
aureus]; hemoglobin oxygen saturation in the blood
(≤ 96 and > 96); spirometry and comorbidities: nasal
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and pancreatic insufficiency (PI).
The clinical score evaluation was performed by two
specialists in double-blind analyses, and in discordance
case, another one was consulted. The Shwachman-
Kulczycki score compares clinical manifestations among
patients, detect treatment effects and aid in the determin-
ation of diagnostic criteria. To that end, the system evalu-
ates 4 major parameters: general activity, nutrition, chest
radiographic findings and physical examination. The score
for each parameter ranges from 5 to 25. Lower score’s
values are associated with CF severity [29]. The BS is a
tomographic scoring system to assess pulmonary involve-
ment, determine therapeutic effects and aid selection of pa-
tients for transplants, with small variation between the
scores given by the various examiners and the score proved
to have good reproducibility and high correlation with pul-
monary function test results. A total of 9 categories, worth
3 points each, are scored, and a maximal score equals aTable 2 Genotypic characteristic of gene polymorphisms at G
mutation among cystic fibrosis patients
Gene Chromosome position Location Varia
GCLC, rs17883901 6p12 Promoter region C
GCLC, rs137852340 6p12 Promoter region A
GSTP1, rs1695 11q13 Exon 5 A
GSTM1 1p13.3 Dele
GSTT1 22q11.23 Dele
















GCLC glutamate-cysteine ligase catalytic subunit, GSTM1 Glutathione S-transferase Mu 1
CFTR Cystic fibrosis transmembrane conductance regulator, C Cytosine, T Thymine, A Ad
% percentage, *p value for Hardy-Weinberg Equilibrium, N number of patients, Wt Wild
1- GCLC, rs17883901 is not in Hardy-Weinberg Equilibrium in our sample.high degree of severity. The final score must be subtracted
from 25. Lower score’s values are associated with CF sever-
ity [29]. Kanga score is a system designed to assess acute
exacerbations of the disease, to predict improvement or
worsening of pulmonary function and to evaluate thera-
peutic effects with little variability between examiners and
correlated significantly with pulmonary function (FEV1 and
forced vital capacity) test results. The system helps identify
daily clinical changes and includes 5 common symptoms
(cough, fluid secretion, appetite loss, dyspnea and frailty)
and 5 physical signs (temperature, weight, respiratory fre-
quency, wheezing and respiratory sounds). Each criterion
is worth 1 to 5 points. Higher score’s values are associated
with CF severity [29].
Spirometry was performed in patients older than 7
years, using the CPFS/D spirometer (MedGraphics, Saint
Paul, Minnesota, USA). Data was recorded by the PF
BREEZE software version 3.8B for Windows 95/98/NT
[32] and the following markers were included: forcedCLC, GSTM1, GSTT1, and GSTP1 genes and CFTR gene
tion Genotype MAF p*
C/C C/T T/T
/T 144 (80%) 29 (16.11%) 7 (3.89%) 0.12 <0.005 1
A/A A/G G/G
/G 118 (65.56%) 56 (31.11%) 6 (3.33%) 0.19 >0.05
/G 97 (53.89%) 74 (41.11%) 9 (5%) 0.26 >0.05
Wt/Wt + Wt/del del/del
tion 108 (60%) 72 (40%)

















, GSTT1 Glutathione S-transferase theta 1, GSTP1 Glutathione S-transferase P1,
enine, G Guanine, < minor than, > bigger than, MAF minor allele frequency,
allele, del deleted allele, (−) CFTR mutation no identified.
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piratory volume in the first second [FEV1(%) - ≤ 72
and > 72], FEV1/FVC(%) - ≤ 86 and > 86] and forced
expiratory flow between 25 and 75% of the FVC
[FEF25-75% - ≤ 57 and > 57].
DNA extraction and polymorphisms genotyping
DNA sample was obtained from peripheral blood using
phenol-chloroform standard procedure. In order to evalu-
ate DNA concentration, we quantified the entire sample
using GE NanoVue™ Spectrophotometer (GE Healthcare
Biosciences, Pittsburgh, USA).
The CFTR gene mutations were investigated by PCR
technique (F508del) and the restriction fragment length
polymorphism (RFLP) method (G542X, R1162X, R553X,Table 3 Genetic interaction of polymorphisms and CFTR muta
Clinical variables Gene
Male/female CFTR*GCLC*GSTP1*GSTT1*GS
Race (caucasian/ no caucasian) CFTR*GCLC*GSTP1*GSTT1*GS
Age CFTR*GCLC*GSTP1*GSTT1*GS
Age for diagnosis CFTR*GCLC*GSTP1*GSTT1*GS
Onset of symptoms geral CFTR*GCLC*GSTP1*GSTT1*GS
digestive CFTR*GCLC*GSTP1*GSTT1*GS
pulmonary CFTR*GCLC*GSTP1*GSTT1*GS
Clinical scores Bhalla CFTR*GCLC*GSTP1*GSTT1*GS
Kanga CFTR*GCLC*GSTP1*GSTT1*GS
Shwachman-Kulczycki CFTR*GCLC*GSTP1*GSTT1*GS
Body mass index CFTR*GCLC*GSTP1*GSTT1*GS
Sputum’s microbiology A. xylosoxidans CFTR*GCLC*GSTP1*GSTT1*GS
P. aeruginosa mucoid CFTR*GCLC*GSTP1*GSTT1*GS
P. aeruginosa no mucoid CFTR*GCLC*GSTP1*GSTT1*GS
S. aureus CFTR*GCLC*GSTP1*GSTT1*GS
B. cepacia CFTR*GCLC*GSTP1*GSTT1*GS
First isolated P. aeruginosa CFTR*GCLC*GSTP1*GSTT1*GS










GCLC glutamate-cysteine ligase catalytic subunit, GST glutathione S-transferase, Testing B
A. xylosoxidans Achromobacter xylosoxidans, B. cepacia Burkolderia cepacia, P. aeruginosa
volume in one second, FVC - forced vital capacity, FEF25-75% forced expiratory flow betw
polymorphism, allele G - GCLC-350A>G and GSTP1+313A>G polymorphisms, deletion a
GSTP1+313A>G, GSTM1 and GSTT1 genes deletion and mutations in the CFTR gene with
MDRPT0.4.7 software.G551D and N1303K). Some mutations in CF patients were
obtained by sequencing or MLPA (Multiplex Ligation -
dependent Probe Amplification) analysis: S4X, 2183A>G,
1717-G>A and I618T. For sequencing and MLPA, we used
the same MegaBace1000® (GE Healthcare Biosciences,
Pittsburgh, USA) [33]. The CFTR genotype separated the
patients in 3 groups: (1) patients with two mutations iden-
tified classes I, II and/or III, (2) patients with one muta-
tions identified classes I, II or III, (3) patients with no
identified mutation. All mutations identified were included
in the class one, two or three of the CFTR gene. Other
identified mutations, class IV (P205S e R334W) were not
included in the statistical analysis.
For the GSTM1 and GSTT1 genes deletion, a multi-
plex PCR reaction was performed and the CYP1A1tions in association with cystic fibrosis clinical variables
Ratio Testing ball. acc. p-value Cross validation consistency
TM1 1 0.5056 0.8506 10/10
TM1 0.0909 0.3909 0.9915 10/10
TM1 0.9889 0.5312 0.6870 10/10
TM1 0.8804 0.4100 0.9989 10/10
TM1 0.7526 0.4286 0.9945 10/10
TM1 0.9737 0.4614 0.9698 10/10
TM1 0.7935 0.5022 0.8566 10/10
TM1 0.9552 0.6824 0.0080# 10/10
TM1 0.9571 0.5131 0.8165 10/10
TM1 0.9 0.5562 0.5474 10/10
TM1 3.45 0.5484 0.6260 10/10
TM1 0.1118 0.4617 0.9418 10/10
TM1 0.7379 0.5505 0.5507 10/10
TM1 1.2949 0.4151 0.9951 10/10
TM1 3.7105 0.5094 0.8317 6/10
TM1 0.1548 0.5277 0.7610 10/10
TM1 0.9552 0.4913 0.8903 7/10
TM1 0.9602 0.5312 0.6904 10/10
TM1 0.9848 0.4746 0.9448 10/10
TM1 0.900 0.4437 0.9833 10/10
TM1 0.9403 0.6426 0.0586 10/10
TM1 0.9848 0.5054 0.8447 10/10
TM1 3.977 0.5266 0.7486 10/10
TM1 0.1776 0.5401 0.6950 10/10
TM1 0.2292 0.5713 0.5139 10/10
TM1 0.2292 0.4527 0.9728 10/10
TM1 0.1959 0.3815 0.9988 10/10
all. Acc. Testing Balance Accuracy, CFTR Cystic Fibrosis Transmembrane Regulator,
Pseudomonas aeruginosa, S. aureus Staplylococcus aures, FEV1 forced expiratory
een 25 and 75% of CVF. 1. Severe variants to polymorphism: allele T, GCLC 129C>T
llele GSTM1 and GSTT1 genes. # Association of GCLC-129C>T, GCLC-350A>G,
the Bhalla Score, p: 0.0080. Statistical analysis performed by the MDR2.0 and
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[34]. In the assay tests for the wild type allele, the
samples for which no signal is obtained are homozy-
gous for the deletion. Heterozygotes and homozygotes
for the wild-type allele cannot be differentiated by the
multiplex technique used. As GSTM1 and GSTT1 de-
letion analyze not provide complete genotypes, minor
allele frequencies and Hardy-Weinberg Equilibrium
cannot be evaluated for these loci in our study. By the
method realized we have two groups of GSTM1 and
GSTT1 gene: (i) patients homozygous to gene deletion; (2)
patients with at least an allele expressed. The RFLP was
performed for polymorphisms GCLC*-129C>T, GCLC*-
3506A>G [10,15] and GSTP1*+313A>G [28].
Other genes were studied in the same CF reference
center with same population as previously published
[11,13,14]. The GSTM1 and GSTT1 genes were studied
in our center considering other CF patients as recent
published data showed [12]. The patient’s studied by
Lima et al. (2012) [12] did not include the same CF
patients, and in the previously study, only the follow
clinical variables were employed: age, sex, ethnic and
Shwachman-Kulczycki.
Statistical analysis
To develop statistical analyses, patients were divided
into two subgroups according to clinical variables distri-
bution. We evaluate minor allele frequency (MAF) and
Hardy-Weinberg equilibrium (HWE) using OEGE softwareFigure 1 Distribution of patients according to different genotype com
GCLC*-129C>T, GCLC*-350A>G, GSTP1*+313A>G, GSTM1 and GSTT1 g
CFTR gene: (MI) Mutation-Identified and (MNI) Mutation-No-Identified to cla
low-risk. In the figure only the polymorphisms with positive interaction wit
by the genes with bigger interaction (GSTM1, GSTT1 and CFTR), and with th
showed, the GCLC*-129C>T, GCLC*-350A>G polymorphisms not show asso
S-transferase; CFTR - Cystic Fibrosis Transmembrane Regulator. The number
example, in the first square one patient (left column – severe BS) has the fo
(ii) deletion of GSTM1 and GSTT1 in homozygous, and (iii) A/A genotype to
patients without the combined genotype presence.(Online Encyclopedia for Genetic Epidemiology studies,
2008). In order to evaluate genetic interaction among the
polymorphisms in our sample, we used the Multifactor Di-
mensionality Reduction (MDR) model, which is a nonpara-
metric and genetic model-free data mining for nonlinear
interaction identification among genetic and environmen-
tal attributes [35-37]. To adjust results for multiple com-
parisons, we performed a MDR permutation test in our
sample, totalizing 100,000 permutations.
Results and discussion
The CF is a disease with a high phenotypic variability,
resulting from the interaction between genetic and envir-
onmental factors, which could affect differential expression
between patients with similar CFTR gene mutations [2].
Despite CF’s severity is difficult to characterize, we describe
28 clinical variables (Table 1), consistent with the pheno-
type feature of the disease.
Analyses of GCLC, GSTM1, GSTT1, and GSTP1 genes
polymorphism is shown in Table 2. The CFTR mutation
showed two different mutations in 85 (47.22%) CF pa-
tients; only one mutation in 51 (28.33%) CF patients and
none mutation in 44 (24.44%) CF patients (Table 2).
The polymorphism GCLC-129C>T is not in Hardy-
Weinberg equilibrium. The MAF observed in present
data is 0.012, and the data achieved at National Center
for Biotechnology Information (www.ncbi.nlm.nih.gov/),
by HapMap project, shows a MAF of 0.076. The ob-
served difference can be a strong factor to consider thebinations for the clustering of mutations in the CFTR gene and
enes deletion polymorphisms with the Bhalla score (BS). For the
ss I, II and/or III. Combinations of high risk are in gray and white to
h the BS are shown. The stronger association with the BS is observed
e GSTP1*+313A>G polymorphism in a weak association. To data
ciation, and are not included in the figure. GST - glutathione
in the figure represents the patients with genotype combination, for
llow genotype: (i) two identified mutation in the CFTR gene,
GSTP1+313A>G polymorphism and three (right column- mild BS)
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but we did not find in our data genotype-phenotype-
association. Maybe, with a bigger population and other
clinical variables can be possible to determine the poly-
morphism influence. Another factor should be consid-
ered that is the Brazilian population is an admixture















Figure 2 Dendrogram and graph of entropy with the genes interactio
A. Dendrogram with the genes interaction and their polymorphisms in res
Bhalla clinical score is given by CFTR mutations and GSTM1 and GSTT1 gen
associated with the clinical variable. Polymorphisms GCLC*-129C>T and GC
measuring the power of different genotypes and the interaction between
The CFTR mutation gene, GSTP1*+313A>G and GSTM1 and GSTT1 deletion
mutation showed influence of 3.38% for BS, the GSTM1 and GSTT1 deletion
showed influence of 0.5%. The CFTR mutation showed a value of 4.15% for
GSTT1 genes and 3.57% for the association with GSTP1*+313A>G. The den
analysis included 180 Cystic Fibrosis patients. # Association of GCLC-129C>
and CFTR mutations with the BS show a p-value of 0.0080. CFTR - Cystic Fib
catalytic subunit; GSTP1 - glutathione S-transferase P1; GSTM1 - glutathione
interaction is show by the distance between the two genes on the figure A
the figure B by the color intensity.The MDR analysis showed evidence of interaction of
GSTM1 and GSTT1 genes deletion, GSTP1*+313A>G,
and CFTR mutations (p= 0.008) and BS clinical score
(Table 3). All data was previously associated with a
point-point analysis considering which gene poly-
morphism in association with one clinical manifest-
ation at a time by CFTR groups, and after Bonferroni


















n and their polymorphisms in response to Bhalla score.
ponse to Bhalla score (BS). The stronger interaction of response to
es deletion. Secondly, the polymorphism GSTP1*+313A> G was
LC*-350A>G were not associated with the BS. B. Graph of entropy
them, for the genes analyzed in the gene-gene interaction with BS.
polymorphisms showed significant association with BS. The CFTR
together, showed 2.82% of influence, while the GSTP1*+313A>G
the interaction between the deletion polymorphism with GSTM1 and
drogram construction was performed by the software MDR2.0. The
T, GCLC-350A>G, GSTP1+313A>G, GSTM1 and GSTT1 genes deletion
rosis Transmembrane Regulator; GCLC - glutamate-cysteine ligase,
S-transferase M1; GSTT1 - glutathione S-transferase T1. The power of
in horizontal direction. The redundancy/synergy power is show in
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Additional file 3: Table S6, Additional file 4: Table S7,
Additional file 5: Table S8). In this context, the data
by gene-gene interaction provides a better tool to contrib-
ute in the clinical manifestation association. The associ-
ation observed cannot identify if those patients who carry
risk alleles at all four loci will have the most severe clinical
phenotype reflected by the BS.
Genotype combinations of the genes that show associ-
ation with BS clinical score are demonstrated in Figure 1.
The largest association regarding to BS clinical response
was given by the interaction of GSTM1 and GSTT1
genes deletion, and CFTR mutations. The polymorphism
GSTP1*+313A>G presented entropy with BS clinical
score, but with minor intensity (Figure 2).
In the study, different clinical markers were analyzed
and the association has found with BS clinical score. The
BS clinical score is a computed tomography, which mea-
sures pulmonary involvement, therapeutic effects and se-
lection of patients for transplantation, which detects
anatomical changes of the lung parenchyma [29,38,39].
The BS has low variation between examiners, good repro-
ducibility, high sensitivity and specificity, and high correl-
ation with pulmonary function test [29]. Values obtained
in the BS can predict severity associated with deterioration
of the structure of the lung parenchyma, which later in
clinical evolution can be observed by other variables such
as BMI and lung function.
The most important cause of mortality and morbidity is
the increase of oxidizing reactions; in this way, understand
the mechanisms associated with this process is important
to the clinical dynamics of the disease and to comprehend
the mechanisms by which the disease shows a variability in
its severity among patients with similar CFTR genotype.
The association of clinical, laboratory, and genetic markers,
such as modifier genes, with CF’s severity can provide bet-
ter understanding of clinical variability finding among
these patients being important in the clinical prognosis. In
addition, further studies should be developed to investigate
the possibility to use products related to GSH pathway as a
possible target of new drugs to CF and also to understand
the oxidative process which takes place in the lungs
of these patients.
Conclusion
The described results with the support of the MDR ana-
lysis tool demonstrated a genetic interaction of CF sever-
ity with the BS, and gene polymorphisms related to GSH
pathway, showing that the BS is an important marker of
CF severity, since it indicates early pulmonary disease, and
contribute to determine patients of a risk group without
the search of other clinical and laboratory markers. In this
context, polymorphisms in genes associated with metabol-
ism of GSH act on the CF’s severity.Additional files
Additional file 1: Table S4. GCLC-129C>T polymorphism in GCLC gene
in association with clinical variables in cystic fibrosis patients distributed
by CFTR mutation.
Additional file 2: Table S5. GCLC-3506A>G polymorphism in GCLC
gene in association with clinical variables in cystic fibrosis patients
distributed by CFTR mutation.
Additional file 3: Table S6. The GSTM1 gene deletion polymorphism in
association with clinical variables in cystic fibrosis patients distributed by
CFTR mutation.
Additional file 4: Table S7. The GSTT1 gene deletion polymorphism in
association with clinical variables in cystic fibrosis patients distributed by
CFTR mutation.
Additional file 5: Table S8. The GSTP1+313A>G polymorphism in
GSTP1 gene in association with clinical variables in cystic fibrosis patients
distributed by CFTR mutation.
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